Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Increasing diversity in dementia research1765
The predictive value and clinical use of the neurological pupillary index – Authors' reply1381
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply1351
Lessons and future directions for GBA1-targeting therapies1136
Resolution of expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study1004
Correction to Lancet Neurol 2025; 24: 850–65715
Correction to Lancet Neurol 2024; 23: 168–77682
Correction to Lancet Neurol 2021; 20: 448–59618
Correction to Lancet Neurol 2020; 19: 391–401605
Implications of the KIWE trial for low-income and lower-middle-income countries588
Dementia diagnosis in the anti-amyloid era514
RAB32 mutation in Parkinson's disease492
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis368
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease351
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study348
Multidisciplinary care for amyotrophic lateral sclerosis339
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r337
The relevance of social and commercial determinants for neurological health297
Correction to Lancet Neurol 2025; 24: 850–65270
Adjunct dexamethasone in herpes simplex virus encephalitis264
Anti-CD19 CAR T cells for refractory myasthenia gravis261
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study257
Global burden of stroke: dynamic estimates to inform action243
Traumatic brain injury research: homogenising heterogeneity234
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial222
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease211
Surrogate endpoints for progressive multifocal leukoencephalopathy209
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment205
Diana Cejas200
Parkinson's disease is a recognisable and useful diagnostic entity200
Aspiring to restore arm and hand function after stroke188
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply180
Albert Kwaku Akpalu173
A chilly tale of dementia168
A nasal CGRP receptor antagonist for acute migraine therapy167
A study in healing the wounds of trauma161
Trials in intracerebral haemorrhage: a path to success?160
Delving into the human mind158
Beyond the modular brain149
Considering the neurological health needs of LGBTQIA people146
A sensitive portrayal of a controversial condition144
Amyotrophic lateral sclerosis from genotoxins alone?142
2025 for neuromuscular diseases: a year of multiple advances142
Guiding the future of neurology: our peer-reviewers in 2025137
Global burden of headache disorders: innovations, disparities, and priorities for action135
The prescription of valproate: risk of harm134
Correction to Lancet Neurol 2023; 22: 812–25134
Correction to Lancet Neurol 2022; 21: 284–94133
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial130
Social connection: a fundamental need for good health129
From stroke awareness to stroke action awareness128
Gene therapy for X-linked myotubular myopathy: the challenges125
Miratul Muqit: leading an alliance to decode Parkinson's disease122
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri120
Deep brain stimulation for the treatment of patients with dystonia: advances towards network-based personalised care120
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases117
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro111
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial107
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment106
Functional or hysterical?103
α-synuclein seed amplification and its uses in Parkinson's disease102
Global burden of meningitis: progress, gaps, and priorities102
Diagnosis and pathogenesis of dystonia: clinical heterogeneity, shared mechanisms, and neurodevelopmental origins101
Personalised neuromodulation in patients with dystonia100
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers98
Multiple sclerosis in 2022: old players, new insights98
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response98
New results for risdiplam in spinal muscular atrophy97
Expansion of stenting indications in the USA97
Responsible innovation in neurology96
Jessica Ailani95
Exploring immunomodulation with azathioprine in Parkinson's disease95
Supporting young carers across neurological disorders94
A proposal for equity neuroscience94
Changing multiple-sclerosis-induced thoughts and behaviours93
Thank you to The Lancet Neurology's peer reviewers in 202592
Learning to be an adult with a disability92
Correction to Lancet Neurol 2024; 23: 110–2289
Cognitive function in people with functional seizures88
Revisiting candesartan: new evidence for an old option in migraine prevention88
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis87
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis – Authors’ reply86
Major advances in Parkinson's disease over the past two decades and future research directions84
1.185478925705